| 2025-11-25 |
详情>>
内部人交易：
LILLY ENDOWMENT INC共交易33笔
|
| 2025-10-30 |
详情>>
股本变动：
变动后总股本94538.38万股
|
| 2025-10-30 |
详情>>
业绩披露：
2025年三季报(累计)每股收益15.60美元,归母净利润140.02亿美元,同比去年增长126.57%
|
| 2025-10-30 |
财报披露：
美东时间 2025-10-30 盘前发布财报
|
| 2025-08-07 |
详情>>
业绩披露：
2025年中报每股收益9.37美元,归母净利润84.20亿美元,同比去年增长61.61%
|
| 2025-05-01 |
详情>>
业绩披露：
2025年一季报每股收益3.07美元,归母净利润27.59亿美元,同比去年增长23.02%
|
| 2025-03-21 |
股东大会：
将于2025-05-05召开股东大会
会议内容 ▼▲
- 1.Election of each of the four director nominees to serve three-year terms
2.Approval, on an advisory basis, of the compensation paid to the company’s named executive officers
3.Ratification of the appointment of Ernst & Young LLP as the independent auditor for 2025
4.Approval of amendments to the company’s articles of incorporation to eliminate the classified board structure
5.Approval of amendments to the company’s articles of incorporation to eliminate supermajority voting provisions
|
| 2025-03-21 |
股东大会：
将于2025-05-05召开股东大会
会议内容 ▼▲
- 1.Election of each of the four director nominees to serve three-year terms
2.Approval, on an advisory basis, of the compensation paid to the company’s named executive officers
3.Ratification of the appointment of Ernst & Young LLP as the independent auditor for 2025
4.Approval of amendments to the company’s articles of incorporation to eliminate the classified board structure
5.Approval of amendments to the company’s articles of incorporation to eliminate supermajority voting provisions
|
| 2025-02-19 |
详情>>
业绩披露：
2024年年报每股收益11.76美元,归母净利润105.90亿美元,同比去年增长102.08%
|
| 2025-02-19 |
详情>>
业绩披露：
2022年年报每股收益6.93美元,归母净利润62.45亿美元,同比去年增长11.88%
|
| 2024-10-30 |
详情>>
业绩披露：
2024年三季报(累计)每股收益6.86美元,归母净利润61.80亿美元,同比去年增长102.58%
|
| 2024-08-08 |
详情>>
业绩披露：
2023年中报每股收益3.45美元,归母净利润31.08亿美元,同比去年增长8.85%
|
| 2024-08-08 |
详情>>
业绩披露：
2024年中报每股收益5.78美元,归母净利润52.10亿美元,同比去年增长67.62%
|
| 2024-04-30 |
详情>>
业绩披露：
2024年一季报每股收益2.49美元,归母净利润22.43亿美元,同比去年增长66.77%
|
| 2024-03-22 |
股东大会：
将于2024-05-06召开股东大会
会议内容 ▼▲
- 1.Election of each of the four director nominees to serve three-year terms
2.Approval, on an advisory basis, of the compensation paid to the company’s named executive officers.
3.Ratification of the appointment of Ernst & Young LLP as the independent auditor for 2024
4.Approval of amendments to the company’s articles of incorporation to eliminate the classified board structure
5.Approval of amendments to the company’s articles of incorporation to eliminate supermajority voting provisions
6.Shareholder proposal to publish an annual report disclosing lobbying activities
7.Shareholder proposal to report on effectiveness of the company’s diversity, equity, and inclusion efforts
8.Shareholder proposal to establish and report on a process by which the impact of extended patent exclusivities on product access would be considered in deciding whether to apply for secondary and tertiary patents
9.Shareholder proposal to adopt a comprehensive human rights policy
|
| 2024-03-22 |
股东大会：
将于2024-05-06召开股东大会
会议内容 ▼▲
- 1.Election of each of the four director nominees to serve three-year terms
2.Approval, on an advisory basis, of the compensation paid to the company’s named executive officers.
3.Ratification of the appointment of Ernst & Young LLP as the independent auditor for 2024
4.Approval of amendments to the company’s articles of incorporation to eliminate the classified board structure
5.Approval of amendments to the company’s articles of incorporation to eliminate supermajority voting provisions
6.Shareholder proposal to publish an annual report disclosing lobbying activities
7.Shareholder proposal to report on effectiveness of the company’s diversity, equity, and inclusion efforts
8.Shareholder proposal to establish and report on a process by which the impact of extended patent exclusivities on product access would be considered in deciding whether to apply for secondary and tertiary patents
9.Shareholder proposal to adopt a comprehensive human rights policy
|
| 2024-02-21 |
详情>>
业绩披露：
2023年年报每股收益5.82美元,归母净利润52.40亿美元,同比去年增长-16.08%
|
| 2023-11-02 |
详情>>
业绩披露：
2023年三季报(累计)每股收益3.39美元,归母净利润30.51亿美元,同比去年增长-29.17%
|
| 2023-03-17 |
股东大会：
将于2023-05-01召开股东大会
会议内容 ▼▲
- 1.Election of each of the four director nominees to serve three-year terms
2.Approval, on an advisory basis, of the compensation paid to the company’s named executive officers
3.Advisory vote on frequency of future advisory votes on named executive officer compensation
4.Ratification of the appointment of Ernst & Young LLP as the independent auditor for 2023
5.Approval of amendments to the company’s articles of incorporation to eliminate the classified board structure
6.Approval of amendments to the company’s articles of incorporation to eliminate supermajority voting provisions
7.Shareholder proposal to publish an annual report disclosing lobbying activities
8.Shareholder proposal to eliminate supermajority voting requirements
9.Shareholder proposal to establish and report on a process by which the impact of extended patent exclusivities on product access would be considered in deciding whether to apply for secondary and tertiary patents
10.Shareholder proposal to report on risks of supporting abortion
11.Shareholder proposal to disclose lobbying activities and alignment with public policy positions and statements
12.Shareholder proposal to report on effectiveness of the company’s diversity, equity, and inclusion efforts
13.Shareholder proposal to adopt a policy to require certain third-party organizations to annually report expenditures for political activities before Lilly contributes to an organization
|
| 2023-03-17 |
股东大会：
将于2023-05-01召开股东大会
会议内容 ▼▲
- 1.Election of each of the four director nominees to serve three-year terms
2.Approval, on an advisory basis, of the compensation paid to the company’s named executive officers
3.Advisory vote on frequency of future advisory votes on named executive officer compensation
4.Ratification of the appointment of Ernst & Young LLP as the independent auditor for 2023
5.Approval of amendments to the company’s articles of incorporation to eliminate the classified board structure
6.Approval of amendments to the company’s articles of incorporation to eliminate supermajority voting provisions
7.Shareholder proposal to publish an annual report disclosing lobbying activities
8.Shareholder proposal to eliminate supermajority voting requirements
9.Shareholder proposal to establish and report on a process by which the impact of extended patent exclusivities on product access would be considered in deciding whether to apply for secondary and tertiary patents
10.Shareholder proposal to report on risks of supporting abortion
11.Shareholder proposal to disclose lobbying activities and alignment with public policy positions and statements
12.Shareholder proposal to report on effectiveness of the company’s diversity, equity, and inclusion efforts
13.Shareholder proposal to adopt a policy to require certain third-party organizations to annually report expenditures for political activities before Lilly contributes to an organization
|
| 2023-01-24 |
复牌提示：
2023-01-24 09:30:15 停牌，复牌日期 2023-01-24 09:38:25
|
| 2022-03-18 |
股东大会：
将于2022-05-02召开股东大会
会议内容 ▼▲
- 1.Election of each of the three director nominees to serve three-year terms
2.Approval, on an advisory basis, of the compensation paid to the company's named executive officers
3.Ratification of the appointment of Ernst & Young LLP as the independent auditor for 2022
4.Approval of amendments to the company’s Articles of Incorporation to eliminate the classified board structure
5.Approval of amendments to the company’s Articles of Incorporation to eliminate supermajority voting provisions
6.Approval of amendments to the company's Articles of Incorporation to give shareholders the ability to amend the company's bylaws
7.Shareholder proposal to amend the bylaws to require an independent board chair, if properly presented at the meeting
8.Shareholder proposal to publish an annual report disclosing lobbying activities, if properly presented at the meeting
9.Shareholder proposal to disclose lobbying activities and alignment with public policy positions and statements, if properly presented at the meeting
10.Shareholder proposal to report oversight of risks related to anticompetitive pricing strategies, if properly presented at the meeting
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-03-19 |
股东大会：
将于2021-05-03召开股东大会
会议内容 ▼▲
- 1.Election of each of the five director nominees to serve three-year terms
2.Approval, on an advisory basis, of the compensation paid to the company's named executive officers
3.Ratification of the appointment of Ernst & Young LLP as the independent auditor for 2021
4.Approval of amendments to the company’s Articles of Incorporation to eliminate the classified board structure
5.Approval of amendments to the company’s Articles of Incorporation to eliminate supermajority voting provisions
6.Shareholder proposal to disclose direct and indirect lobbying activities and expenditures, if properly presented at the meeting
7.Shareholder proposal to amend the bylaws to require an independent board chair, if properly presented at the meeting
8.Shareholder proposal to implement a bonus deferral policy, if properly presented at the meeting
9.Shareholder proposal to disclose clawbacks on executive incentive compensation due to misconduct, if properly presented at the meeting
|
| 2020-03-20 |
股东大会：
将于2020-05-04召开股东大会
会议内容 ▼▲
- 1.Election of the five directors listed in the proxy statement to serve three-year terms
2.Approval, by non-binding vote, of the compensation paid to the company's named executive officers
3.Ratification of Ernst & Young LLP as the independent auditor for 2020
4.Approve amendments to the Articles of Incorporation to eliminate the classified board structure
5.Approve amendments to the Articles of Incorporation to eliminate supermajority voting provisions
6.Shareholder proposal to disclose direct and indirect lobbying activities and expenditures
7.Shareholder proposal to publish a report on the effectiveness of the forced swim test
8.Shareholder proposal to amend the bylaws to require an independent board chair
9.Shareholder proposal on board diversity requesting disclosures of specific minimum qualifications and board nominee skills, experience, and ideological perspective
10.Shareholder proposal to publish feasibility report on incorporating public concern over drug prices into senior executive compensation arrangements
11.Shareholder proposal to implement a bonus deferral policy
12.Shareholder proposal to disclose clawbacks on executive incentive compensation due to misconduct
|
| 2019-12-16 |
除权日：
美东时间 2020-02-13 每股派息0.74美元
|
| 2019-10-21 |
除权日：
美东时间 2019-11-14 每股派息0.65美元
|
| 2019-06-19 |
除权日：
美东时间 2019-08-14 每股派息0.65美元
|
| 2019-05-06 |
除权日：
美东时间 2019-05-16 每股派息0.65美元
|
| 2019-03-22 |
股东大会：
将于2019-05-06召开股东大会
会议内容 ▼▲
- 1.Election of the four directors listed in the proxy statement to serve three-year terms
2.Approval, by non-binding vote, of the compensation paid to the company's named executive officers
3.Ratification of Ernst & Young LLP as the principal independent auditors for 2019
4.Approve amendments to the Articles of Incorporation to eliminate the classified board structure
5.Approve amendments to the Articles of Incorporation to eliminate all supermajority voting provisions
6.Shareholder proposal requesting a report regarding direct and indirect political expenditures
|
| 2018-12-19 |
除权日：
美东时间 2019-02-14 每股派息0.65美元
|
| 2018-10-15 |
除权日：
美东时间 2018-11-14 每股派息0.56美元
|
| 2018-06-18 |
除权日：
美东时间 2018-08-14 每股派息0.56美元
|
| 2018-05-07 |
除权日：
美东时间 2018-05-16 每股派息0.56美元
|
| 2018-03-19 |
股东大会：
将于2018-05-07召开股东大会
会议内容 ▼▲
- 1.Election of the five directors listed in this proxy statement to serve three-year terms.
2.Approval, by non-binding vote, of the compensation paid to the company's named executive officers.
3.Ratification of Ernst & Young LLP as the principal independent auditor for 2018.
4.Approve amendments to the Articles of Incorporation to eliminate the classified board structure.
5.Approve amendments to the Articles of Incorporation to eliminate supermajority voting provisions.
6.Approve the Amended and Restated 2002 Lilly Stock Plan.
7.Shareholder proposal seeking support for the descheduling of cannabis.
8.Shareholder proposal requesting report regarding direct and indirect political contributions.
9.Shareholder proposal requesting report on policies and practices regarding contract animal laboratories.
10.Shareholder proposal requesting report on extent to which risks related to public concern over drug pricing strategies are integrated into incentive compensation arrangements.
|
| 2017-12-11 |
除权日：
美东时间 2018-02-14 每股派息0.56美元
|
| 2017-10-16 |
除权日：
美东时间 2017-11-14 每股派息0.52美元
|
| 2017-06-19 |
除权日：
美东时间 2017-08-11 每股派息0.52美元
|
| 2017-05-01 |
除权日：
美东时间 2017-05-11 每股派息0.52美元
|
| 2017-03-20 |
股东大会：
将于2017-05-01召开股东大会
会议内容 ▼▲
- 1.Election of the five directors listed in the proxy statement to serve three-year terms
2.Approval, by non-binding vote, of the compensation paid to the company's named executive officers
3.Advisory vote regarding the frequency of future advisory votes on named executive officer compensation
4.Ratification of Ernst & Young LLP as the principal independent auditors for 2017
5.Proposal to amend the Lilly Directors' Deferral Plan
6.Shareholder proposal seeking report regarding direct and indirect political contributions
|
| 2016-12-12 |
除权日：
美东时间 2017-02-13 每股派息0.52美元
|
| 2016-10-17 |
除权日：
美东时间 2016-11-10 每股派息0.51美元
|
| 2016-06-20 |
除权日：
美东时间 2016-08-11 每股派息0.51美元
|
| 2016-05-02 |
除权日：
美东时间 2016-05-11 每股派息0.51美元
|
| 2016-03-21 |
股东大会：
将于2016-05-02召开股东大会
会议内容 ▼▲
- 1.Election of the five directors listed in the proxy statement to serve three-year terms
2.Approval, by non-binding vote, of the compensation paid to the company's named executive officers
3.Ratification of Ernst & Young LLP as the principal independent auditors for 2016
|
| 2015-12-08 |
除权日：
美东时间 2016-02-10 每股派息0.51美元
|
| 2015-10-19 |
除权日：
美东时间 2015-11-10 每股派息0.50美元
|
| 2015-06-15 |
除权日：
美东时间 2015-08-12 每股派息0.50美元
|
| 2015-05-04 |
除权日：
美东时间 2015-05-14 每股派息0.50美元
|
| 2014-12-15 |
除权日：
美东时间 2015-02-11 每股派息0.50美元
|
| 2014-10-20 |
除权日：
美东时间 2014-11-12 每股派息0.49美元
|
| 2014-06-16 |
除权日：
美东时间 2014-08-13 每股派息0.49美元
|
| 2014-05-05 |
除权日：
美东时间 2014-05-13 每股派息0.49美元
|
| 2013-12-16 |
除权日：
美东时间 2014-02-12 每股派息0.49美元
|
| 2013-10-21 |
除权日：
美东时间 2013-11-13 每股派息0.49美元
|
| 2013-06-18 |
除权日：
美东时间 2013-08-13 每股派息0.49美元
|
| 2013-05-06 |
除权日：
美东时间 2013-05-14 每股派息0.49美元
|
| 2012-12-17 |
除权日：
美东时间 2013-02-13 每股派息0.49美元
|
| 2012-10-15 |
除权日：
美东时间 2012-11-13 每股派息0.49美元
|
| 2012-06-19 |
除权日：
美东时间 2012-08-13 每股派息0.49美元
|
| 2012-04-16 |
除权日：
美东时间 2012-05-11 每股派息0.49美元
|
| 2011-12-12 |
除权日：
美东时间 2012-02-13 每股派息0.49美元
|
| 2011-10-17 |
除权日：
美东时间 2011-11-10 每股派息0.49美元
|
| 2011-06-20 |
除权日：
美东时间 2011-08-11 每股派息0.49美元
|
| 2011-04-18 |
除权日：
美东时间 2011-05-11 每股派息0.49美元
|
| 2010-12-13 |
除权日：
美东时间 2011-02-11 每股派息0.49美元
|
| 2010-10-18 |
除权日：
美东时间 2010-11-10 每股派息0.49美元
|
| 2010-06-21 |
除权日：
美东时间 2010-08-11 每股派息0.49美元
|